Prospective evaluation of bone density in pregnant women receiving the low molecular weight heparin enoxaparin sodium.
To evaluate changes in bone density in women receiving enoxaparin sodium during pregnancy. Bone density in the proximal femur was serially measured in 16 women receiving enoxaparin sodium (40 mg daily) during pregnancy. Baseline measurements were taken within 2 weeks of starting therapy and then at 6-8 weeks postpartum and 6 months postpartum. Patients received enoxaparin sodium for a mean duration of 25 weeks (range, 19-32 weeks). There was no significant change in mean bone density measurement from baseline measurements to the conclusion of therapy at 6 weeks postpartum and no patient experienced a decrease in bone mass of >10% at 6 weeks postpartum. By 6 months postpartum, there was a significant mean decrease in bone density (P = 0.02) and two of the 14 patients evaluated (14%) experienced an overall bone loss of >10%. The prolonged used of enoxaparin sodium may not cause significant bone loss during pregnancy.